Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)

v3.21.1
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)
9 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Comprehensive Income (Loss) Note [Text Block]

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (Loss):

 

Supplemental Equity

 

The Company has declared cash dividends per share of $0.32 and $ 0.96 in both the three and nine months ended March 31, 2021 and 2020, respectively. 

 

Consolidated Changes in Equity (amounts in thousands)

 

   

Bio-Techne Shareholders

                 
                                   

Accumulated

                 
                   

Additional

           

Other

                 
   

Common Stock

   

Paid-in

   

Retained

   

Comprehensive

   

Noncontrolling

         
   

Shares

   

Amount

   

Capital

   

Earnings

   

Income(Loss)

   

Interest

   

Total

 

Balances at June 30, 2020

    38,453     $ 385     $ 420,536     $ 1,057,470     $ (97,199

)

  $ -     $ 1,381,192  

Cumulative effect adjustments due to adoption of new accounting standards

                            (276

)

                    (276

)

Net earnings

                            33,395                       33,395  

Other comprehensive income

                                    14,057               14,057  

Common stock issued for exercise of options

    117       1       13,727                               13,728  

Common stock issued for restricted stock awards

    25       0       (0

)

    (4,890

)

                    (4,890

)

Cash dividends

                            (12,336

)

                    (12,336

)

Stock-based compensation expense

                    12,667                               12,667  

Common stock issued to employee stock purchase plan

    6       0       1,463                               1,463  

Employee stock purchase plan expense

                    286                               286  

Balances at September 30, 2020

    38,601     $ 386     $ 448,679     $ 1,073,362     $ (83,142

)

  $ -     $ 1,439,285  

Non-controlling interest in Eminence

                                            8,985       8,985  

Net earnings

                            46,274               (130

)

    46,144  

Other comprehensive income

                                    18,904       83       18,987  

Common stock issued for exercise of options

    161       2       16,748       (2,482

)

                    14,268  

Common stock issued for restricted stock awards

    3       0       (0

)

    0                       0  

Cash dividends

                            (12,392

)

                    (12,392

)

Stock-based compensation expense

                    15,471                               15,471  

Employee stock purchase plan expense

                    106                               106  

Balances at December 31, 2020

    38,765     $ 388     $ 481,004     $ 1,104,762     $ (64,238

)

  $ 8,938     $ 1,530,854  
Net earnings                             45,782               (380 )     45,402  
Other comprehensive income                                     215       (69 )     146  
Share repurchases     (120 )     (1 )             (43,177 )                     (43,178 )
Common stock issued for exercise of options     195       2       21,324       (4,332 )                     16,994  
Common stock issued for restricted stock awards     10       0       (0 )     (1,801 )                     (1,801 )
Cash dividends                             (12,446 )                     (12,446 )
Stock-based compensation expense                     10,232                               10,232  
       Common Stock issued to employee stock purchase plan     4       0       1,328                               1,328  

Employee stock purchase plan expense

                    411                               411  
Balances at March 31, 2021     38,854     $ 389     $ 514,299     $ 1,088,788     $ (64,023 )   $ 8,489     $ 1,547,942  

 

                                   

Accumulated

         
                   

Additional

           

Other

         
   

Common Stock

   

Paid-in

   

Retained

   

Comprehensive

         
   

Shares

   

Amount

   

Capital

   

Earnings

   

Income(Loss)

   

Total

 

Balances at June 30, 2019

    37,934     $ 379     $ 316,797     $ 931,934     $ (83,521

)

  $ 1,165,589  

Cumulative effect adjustments due to adoption of new accounting standards and other

                            (879

)

            (879

)

Net earnings

                            14,398               14,398  

Other comprehensive loss

                                    (8,106

)

    (8,106

)

Common stock issued for exercise of options

    94       1       7,854                       7,855  

Common stock issued for restricted stock awards

    50       0       (0

)

    (1,926

)

          (1,926

)

Cash dividends

                            (12,169

)

          (12,169

)

Stock-based compensation expense

                    8,267                       8,267  

Common stock issued to employee stock purchase plan

    6       0       1,096                       1,096  

Employee stock purchase plan expense

                    99                       99  

Balances at September 30, 2019

    38,084     $ 381     $ 334,112     $ 931,358     $ (91,627

)

  $ 1,174,224  

Net earnings

                            119,622               119,622  

Other comprehensive loss

                                    13,275       13,275  

Common stock issued for exercise of options

    195       2       18,293                       18,295  

Common stock issued for restricted stock awards

    4       0       (0

)

                    0  

Cash dividends

                            (12,197

)

            (12,197

)

Stock-based compensation expense

                    10,017                       10,017  

Common stock issued to employee stock purchase plan

                                               

Employee stock purchase plan expense

                    112                       112  

Balances at December 31, 2019

    38,283     $ 383     $ 362,534     $ 1,038,783     $ (78,352

)

  $ 1,323,348  
Net earnings                             36,432               36,432  
Other comprehensive income (loss)                                     (25,105 )     (25,105 )
Share Repurchases     (279 )     (3)       0       (50,109 )             (50,112 )
Common stock issued for exercise of options     100       1       10,026                       10,027  
Common stock issued for restricted stock awards     1       0       (0 )     (114 )             (114 )
Cash dividends                             (12,279 )             (12,279 )
Stock-based compensation expense                     7,745                       7,745  
Common stock issued to employee stock purchase plan     8       0       1,216                       1,216  
Employee stock purchase plan expense                     110                       110  
Balances at March 31, 2020     38,112     $ 381     $ 381,632     $ 1,012,713     $ (103,458 )   $ 1,291,268  

 

Accumulated Other Comprehensive Income

 

The components of other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. The Company reclassified $5.5 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the nine months ended March 31, 2021. The Company reclassified $1.6 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the nine months ended March 31, 2020.

 

The accumulated balances related to each component of other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows:

 

   

Unrealized

Gains

(Losses) on

Derivative

Instruments

   

Foreign

Currency

Translation

Adjustments

   

Total

 

Balance as of June 30, 2020 attributable to Bio-Techne

  $ (13,253

)

  $ (83,946

)

  $ (97,199

)

Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne

    (13 )     27,686       27,673  

Reclassification from loss on derivatives to earnings, net of taxes, attributable to Bio-Techne(1)

    5,503       -       5,503  

Balance as of March 31, 2021 attributable to Bio-Techne(3)

  $ (7,763

)

  $ (56,260

)

  $ (64,023

)

 

 

   

Unrealized

Gains

(Losses) on

Derivative

Instruments

   

Foreign

Currency

Translation

Adjustments

   

Total

 

Balance as of June 30, 2019 attributable to Bio-Techne

  $ (9,537

)

  $ (73,983

)

  $ (83,521

)

Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne

    (6,413 )     (15,138 )     (21,551 )

Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(2)

    1,614       -       1,614  

Balance as of March 31, 2020 attributable to Bio-Techne(3)

  $ (14,336

)

  $ (89,121

)

  $ (103,458

)

 

(1) Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $6,662 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 in the nine months ended March 31, 2021. The Company also recorded a related tax benefit of $1,670 during the nine months ended March 31, 2021.

(2) The Company reclassified ($2,102) to interest expense and a related tax benefit tax of $488 during the nine months ended  March 31, 2020.

(3) The Company had deferred tax benefits of $2,394 and $4,390 included in the accumulated other comprehensive income loss as of March 31, 2021 and  March 31, 2020, respectively.